<DOC>
	<DOCNO>NCT02058472</DOCNO>
	<brief_summary>Study Design : randomize , open label , single-dose , 2-way cross-over design Phase : Phase I</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic &amp; Safety Study G3041 SEVIKAR® Tablet Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>healthy volunteer age 19 55 year old 19 ≤ BMI ≤ 27 neither congenital/chronic disease pathological symptoms/findings result medical examination doctor determine suitable subject within 4 week ago administration Hypersensitivity ( history hypersensitivity ) amlodipine olmesartan Exceed 1.5 time upper limit reference range AST , ALT , total bilirubin , γGT Excessive drinking ( exceed alcohol 140g/week ) Excessive caffeine ( exceed 4cups/day ) grape fruit/orange juice ( exceed 1cup/day ) Smoking 10 cigarette per day</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>